Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
27 Outubro 2023 - 2:31AM
Press Release: Specialty Care growth, strong launch uptake of
Beyfortus® and ALTUVIIIO® drive solid Q3 results
Specialty Care growth, strong launch uptake of Beyfortus® and
ALTUVIIIO® drive solid Q3 results
Paris, October 27, 2023
Q3 2023 sales growth of 3.2% at CER and business
EPS(1) decrease
of 2.1% at CER
- Specialty Care grew 13.5% driven by
Dupixent® (€2,847 million, +32.8%) and ALTUVIIIO® more than
offsetting the impact of Aubagio® generic competition in the
U.S.
- Stable Vaccines sales (-0.6%)
benefited from strong Beyfortus® launch offsetting lower influenza
vaccines sales
- General Medicines core assets grew
3.1%, non-core assets declined mainly due to Lantus® (€343 million,
-32.9%)
- CHC sales grew 4.6% driven by
Digestive Wellness and Allergy categories
- Business EPS(1) of €2.55, down
11.5% on a reported basis and down 2.1% at CER with Aubagio®
LOE
- IFRS EPS of €2.01 (up 21.1%)
Key R&D milestones and regulatory
achievements in Q3
- Beyfortus® U.S. approval for
prevention of RSV lower respiratory tract disease in infants
- ALTUVIIIO® approval for hemophilia
A in Japan and Nexviazyme® for the treatment of Pompe disease in
China
Progress on Corporate Social
Responsibility strategy in Q3
- Sanofi Global Health Unit: first
deliveries of cardio-metabolic products under the Impact brand to
the Republic of Djibouti and to global non-governmental
organizations
Full-year 2023 business EPS guidance
reiterated
- Sanofi expects
2023 business EPS(1) to grow mid single-digit(2) at CER, barring
unforeseen major adverse events. Applying average October 2023
exchange rates, the currency impact on 2023 business EPS is
estimated between -6.0% to -7.0%. This guidance includes
approximately €400 million of expected one-off COVID vaccine
revenues in the fourth quarter.
Paul Hudson, Sanofi Chief Executive Officer,
commented:
“The continued impressive performance of
Dupixent®, the highly anticipated launch of Beyfortus® for the
protection of all infants against RSV and the strong uptake of
ALTUVIIIO® in hemophilia were key drivers in the quarter,
exemplifying our successful strategy execution towards sustainable
growth from innovative medicines. The underlying strength of our
growth drivers more than offset the expected impact from generic
competition on Aubagio® in U.S. and lower sales from mature
products across the General Medicines portfolio in the quarter.
With our two recent business development deals in immunology and
vaccines, we are further strengthening the core of our innovative
pipeline and follow our strategic focus of transforming the
practice of medicine through breakthrough science. As we enter a
compelling next chapter of our company’s Play to Win strategy, we
remain confident in the outlook for the last quarter and
consequently keep our full-year earnings guidance unchanged.”
|
Q3 2023 |
Change |
Change at CER |
9M 2023 |
Change |
Change at CER |
IFRS net sales
reported |
€11,964m |
-4.1% |
+3.2% |
€32,151m |
-0.4% |
+3.9% |
IFRS net income
reported |
€2,525m |
+21.6% |
_ |
€5,955m |
+13.2% |
— |
IFRS EPS reported |
€2.01 |
+21.1% |
_ |
€4.76 |
+13.3% |
— |
Free cash flow(3) |
€1,853m |
-31.2% |
_ |
€4,982m |
-16.1% |
— |
Business
operating income |
€4,028m |
-10.4% |
-1.0% |
€10,087m |
-2.2% |
+4.1% |
Business net
income(1) |
€3,196m |
-11.4% |
-1.9% |
€8,072m |
-1.6% |
+4.8% |
Business EPS(1) |
€2.55 |
-11.5% |
-2.1% |
€6.45 |
-1.5% |
+4.9% |
Changes in net sales are expressed at constant
exchange rates (CER) unless otherwise indicated (definition in
Appendix 7). (1) In order to facilitate an understanding of
operational performance, Sanofi comments on the business net income
statement. Business net income is a non-IFRS financial measure
(definition in Appendix 7). The consolidated income statement for
Q3 2023 is provided in Appendix 3 and a reconciliation of reported
IFRS net income to business net income is set forth in Appendix 4;
(2) 2022 business EPS was €8.26; (3) Free cash flow is a non-IFRS
financial measure (definition in Appendix 7).
Sanofi Enters Next Chapter of Play to Win Strategy
-
Increases investments in its pipeline to fully realize long-term
growth potential, bolstered by successful launches and R&D
progress.
-
Launches strategic cost initiatives, with most of the savings to be
reallocated to fund innovation and growth drivers.
-
Announces intention to separate the Consumer Healthcare Business at
the earliest in Q4 2024 via the creation of a publicly listed
entity1 headquartered in France.
-
Reiterates capital allocation policy and 2023 Business EPS growth
target, and provides preliminary 2024 and 2025
outlook.
Sanofi’s press release on Next Chapter of Play
to Win Strategy can be found at:
https://www.sanofi.com/en/media-room/press-releases
1 Subject to markets conditions and consultations of social
partners and work councils.
Sanofi (BIT:1SAN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Sanofi (BIT:1SAN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024